![](https://www.fondazionemichelangelo.org/wp-content/uploads/2022/12/News_1-300x180.jpg)
Long-term survival data from DESTINY-Breast03 trial
With a longer follow-up of 41 months, trastuzumab-deruxtecan continues to demonstrate superior efficacy over trastuzumab-emtansine in HER2+ metastatic breast cancer
With a longer follow-up of 41 months, trastuzumab-deruxtecan continues to demonstrate superior efficacy over trastuzumab-emtansine in HER2+ metastatic breast cancer
A retrospective analysis of patients treated with locoregional therapy but without adjuvant or neoadjuvant chemotherapy shows that a higher TIL abundance is associated with better survival
A PET-based, pathological complete response-adapted strategy leads to excellent 3-year invasive disease-free survival, with a third of patients who can safely omit chemotherapy
In the phase II aceIERA trial, giredestrant was well tolerated and showed a trend toward favorabile benefit among ESR-1 mutated tumors
Addition of palbociclib to fulvestrant did not improve progression-free survival, whereas addition of palbociclib and avelumab had positive effects: results of the PACE trial
With the passing of Pinuccia Valagussa, co-founder of the Michelangelo Foundation, the field of medicine loses one of the key figures of a season that set the stage of modern clinical oncology